FDA Criticized for Working Too Closely With Biotech Company to Approve Alzheimer’s Drug
New findings from a congressional investigation into the Food and Drug Administration and the biotech company Biogen find that the FDA broke its own protocols to approve a new Alzheimer’s drug last year. The findings conclude that the regulator worked too closely with Biogen, despite significant concerns over the limited and side effects of the […]
